AstraZeneca Taps Dotmatics Platform for Neuroscience Drug Discovery | GenomeWeb

Dotmatics said this week that AstraZeneca's Neuroscience Innovative Medicines Unit has selected its platform to manage research data associated with its collaborative drug discovery efforts.

Dotmatics platform will provide a single point of access to all data and functions for AstraZeneca and its partners, the company said. These users will have access to compound registration and tracking tools, biological screening, DMPK analysis, as well as a fully integrated chemistry and biology electronic laboratory notebook and project management capabilities.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.